|By PR Newswire||
|September 2, 2013 10:31 AM EDT||
NEW YORK, Sept. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Medicines for bowel inflammation - you explore R&D and potential salesWhat's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential revenues.
In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging technologies. Try our new report.
Analysis of what shapes the IBD drugs industry and determines its potential
Discover what the future holds for agents treating inflammatory bowel disorders: Crohn's disease and ulcerative colitis. Read on, then, to explore that drug industry and see what its future market could be worth.
Forecasts to 2023 and other data show you commercial potentials
Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 74 tables, 34 charts, and three interviews.
You know how hard it can be to find data. All that searching. Now, though, you can stay ahead in knowledge for IBD medicine, benefiting your research, analyses, and decisions.
Avoid falling behind. Also save time. Finding information you need just got easier. There, in our study, you hear what's happening and see where the money lies.
The following sections, then, show what you get in our new investigation.
Prospects for the world market and submarkets for IBD medicationsOur report shows revenue to 2023 for the overall world IBD drug market. It also shows you individual forecasts for five submarkets:
• Biologic therapies (biological drugs)
How will those colonic medicines perform? Which classes of lower-gut treatment will generate most money? There you assess prospects for revenue growth.
Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential for those intestinal medicines. See how you can benefit.
You also find revenue predictions for leading products.
Forecasts for IBD drugs - what outlooks for sales?
How will top drugs perform to 2023 at world level? Our report forecasts individual revenues of 14 products, including these:• Humira• Remicade• Asacol• Pentasa• Lialda• Tysabri• Xifaxan• Cimzia• Entocort.
There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you examine competition. You see what's happening, then, understanding trends, competition, challenges, and opportunities.
Our investigation also divides its overall IBD world forecast into geographical regions.
National markets for treating those gastrointestinal disorders
Developments worldwide expand the inflammatory bowel treatment market. Hear about the best revenue prospects.
In developed and developing countries, many opportunities for producers and sellers of those drugs will occur from 2013 to 2023. See where and how.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:• US• Japan• Germany, France, UK, Italy, and Spain (EU5)• China, India, Brazil, and Russia (BRIC).
There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape.
Research and development - assess innovation, trends, and possibilitiesWhat about R&D - pipelines for new drugs? You assess trends there, including for these agents:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF alpha inhibitors
• Stem cell therapies
• Chemokine receptors
• Antioxidants and barrier function therapies.
That R&D explores many molecular pathways and targets. It holds promise. You hear about innovations there - developments and their significance. Discover progress.
For large companies and specialty pharma firms there exist many opportunities. Our new study explains, discussing issues to help your work.
Issues affecting manufacturing and selling of IBD treatmentsOur report also shows you issues and events affecting that industry and market from 2013, including these:
• Nature of ulcerative colitis and Crohn's disease
• Aetiology and epidemiology of IBD
• Monoclonal antibodies (mAbs) as medications
• Delivery systems for agents
• Vaccines and alternative therapy
• Genotyping and improvements to treatments.
There you explore political, economic, social, and technological questions, assessing outlooks for the business. You also analyse that industry's strengths, weaknesses, opportunities, and threats. Discover now what the future holds.
Companies leading that industry and 2017 market value
From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our study predicts the world market for IBD drugs will reach $9.6bn in 2017, and expand further to 2023.
Our work shows you what technologies, products, and organisations hold greatest potential. In particular, it investigates these companies:
• Janssen Biotech
• Warner Chilcott
• Shire Pharmaceuticals.
From 2013 there exist prospects for new drugs and overall sales growth. Our report shows you the possibilities, helping you stay ahead.
Eight ways Inflammatory Bowel Diseases: World Drug Market 2013-2023 helps you
To sum up, then, our research and analysis give you the following knowledge:• Revenue to 2023 of the world market for IBD medicines - discover that industry's overall sales potential• Revenues to 2023 for 5 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales• Revenues to 2023 for 14 products - find sales outlooks for top brands, seeing how they can compete and succeed• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth• Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks• Review of R&D - explore progress in research and development, finding technological and medical possibilities• Interviews with authorities on the field - discover debates and opinions to help you stay ahead• Competition and opportunities - investigate what shapes that market's future, including ways to develop business and succeed.
Information found nowhere else
That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity for treating those gastrointestinal diseases. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.
Treatment of IBD - assess its potential now, seeing what you can gainOur new study shows you data, trends, opportunities, and sales predictions for drugs treating inflammatory bowel disorders. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6
Table of Contents1. Executive Summary 1.1 Inflammatory Bowel Disease Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods
2. Introduction to the Inflammatory Bowel Disease Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Are There Different Types of IBD?
2.3 Signs, Symptoms and Associated Conditions
2.4 What Causes Inflammatory Bowel Disease?
2.5 How Common is Inflammatory Bowel Disease?
3. Drug Treatments for Inflammatory Bowel Diseases
3.1 Can IBD be Cured?
3.2 What Are the Medications Used to Treat IBD?
3.2.1 Aminosalicylates - The Most Common Therapy
3.2.2 Corticosteroids - Limited in the Long-Run?
3.2.3 Immunomodulators - Slow to Act?
3.2.4 Monoclonal Antibodies - The Future?
3.2.5 Antibiotics - Do they Really Help?
3.3 Treatment Protocol
4. The World Inflammatory Bowel Disease Market, 2013-2023
4.1 The Inflammatory Bowel Disease Market in 2012: Domination of Biologics and Aminosalicylates
4.2 Forecast 2013-2023: Any Major Changes Expected?
4.3 Aminosalicylates Forecast 2013-2023: The Work-Horse of IBD Therapy
4.4 Antibiotics Forecast 2013-2023: Will They Still Be Relevant in a Decade?
4.5 Biologic Therapies Forecast 2013-2023: Main Driver of Growth
4.6 Corticosteroids Forecast 2013-2023: Continued Insignificance?
4.7 Immunomodulators Forecast 2013-2023
5. Leading National Markets, 2013-2023
5.1 IBD Drugs - Leading National Markets, 2012
5.2 The US IBD Drug Market, Revenues 2013-2023 - Leader of the Pack
5.2.1 Case Study: What is the Relative Contribution of Ulcerative Colitis and Crohn's Disease to Total IBD Spending in the US?
5.3 The Japanese IBD Drug Market, Revenues 2013-2023 - Tomorrow's Leader?
5.4 The EU-5 IBD Drug Markets, Revenues 2013-2023 - Europe's Growth Potential
5.5 IBD Drug Markets in BRIC Countries, Revenues 2013-2023 - Vast Potential for Sales
5.5.1 Brazil: Revenues 2013-2023
5.5.2 Russia: Revenues 2013-2023
5.5.3 India: Revenues 2013-2023
5.5.4 China: Revenues 2013-2023
6. Market Prospects for Leading IBD Drugs, 2013-2023
6.1 Humira (AbbVie) - The Leading Therapy
6.1.1Humira: Forecast and Analysis, 2013-2023
6.2 Remicade (Janssen Biotech) - A Worthy Challenger?
6.2.1Remicade: Forecast and Analysis, 2013-2023
6.3 Asacol (Warner Chilcott) - The Best Mesalazine Formulation?
6.3.1Asacol: Forecast and Analysis, 2013-2023
6.4 Pentasa (Shire USA) - When Will a Generic Substitute Arrive?
6.4.1 Pentasa: Forecast and Analysis, 2013-2023
6.5 Lialda (Shire USA) - What Potential for that Medication?
6.5.1 Lialda: Forecast and Analysis, 2013-2023
6.6 Tysabri (Elan Pharmaceuticals) - Will Side Effects Prove Too Much?
6.6.1 Tysabri: Forecast and Analysis, 2013-20236.7 Xifaxan (Salix Pharmaceuticals)
6.7.1 Xifaxan: Forecast and Analysis, 2013-20236.8 Cimzia (UCB Inc.) - Approved in Only a Handful of Countries
6.8.1 Cimzia: Forecast and Analysis, 2013-2023
6.9 Entocort (AstraZeneca) - Prominent Steroid Treatment
6.9.1 Entocort: Forecast and Analysis, 2013-2023
6.10 Neoral (Novartis) - A Widely Used Immunosuppressant
6.10.1 Neoral: Forecast and Analysis, 2013-2023
6.11 Medrol (Pfizer Inc.) - Another Leading Steroid
6.11.1 Medrol: Forecast and Analysis, 2013-2023
6.12 Canasa/Salofalk (Aptalis Pharmaceuticals) - A Slow Decline
6.12.1 Canasa/Salofalk: Forecast and Analysis, 2013-2023
6.13 Apriso (Salix Pharmaceuticals) - A Serious Challenger to Asacol?
6.13.1 Apriso: Forecast and Analysis, 2013-2023
6.14 Azulfidine (Pfizer Inc.) - What Scope for Revenue Growth?
6.14.1 Azulfidine: Forecast and Analysis, 2013-2023
7. The R&D Pipeline for Inflammatory Bowel Disease, 2013
7.1 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation
7.1.1 Profile: Vidofludimus (4SC)
7.2 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue
7.2.1 Profile: Etrolizumab (Roche)
7.3 TNF-? Inhibitors - A Tried and Tested Target
7.3.1 Profile: Ozoralizumab (Ablynx)
7.4 Stem Cell Therapies - Basis for a Cure?
7.4.1 Profile: Remestemcel-L (Osiris Therapeutics)
7.5 Janus Kinase (JAK) Inhibitors - More Targets to Hit
7.5.1 Profile: Tasocitinib (Pfizer)
7.6 Immunomodulators - Will They Live Up To the Hype?
7.6.1 Profile: ZP1848 (Zealand Pharma)
7.7 Chemokine Receptors - Potential Exists
7.7.1 Profile: Vercirnon (ChemoCentryx/GSK)
7.8 Antioxidants and Barrier Function
7.8.1 Profile: Tetomilast (Otsuka) - The Future of IBD Treatment?
8. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2013-2023
8.1 SWOT and STEP Analysis of the IBD Market
8.2 What Factors Will Drive the IBD Market?
8.2.1 Increasing Disease Incidence
8.2.2 Better Diagnosis
8.2.3 Nature of the Disease
8.2.4 Delivery Systems
8.2.5 Biological Drugs
8.2.6 Socioeconomic Costs of IBD
8.3 What Factors Will Restrain the Market?
8.3.1 Lack of Understanding of Disease Aetiology
8.3.3 Limits of Biologics
8.3.4 A Cure or Vaccine
8.3.5 The Possible Development of Alternative Treatments
8.3.6 Surgery - When Other Options Fail
9. Leading Companies in the IBD Market, 2013
9.1 The Largest Companies by Revenue
9.2 AbbVie - The Leader in a Highly Profitable Area
9.3 Janssen Biotech - Tomorrow's Powerhouse?
9.4 Warner Chilcott - A Strong Competitor
9.5 Shire Pharmaceuticals - Still a Major Player in the Future?
10. Research Interviews
10.1 Dr Qamar ul Arfin, Gastroenterologist, Aga Khan University Hospital, Karachi, Pakistan
10.1.1 On Antibiotics in Treating IBD
10.1.2 On the Emergence of Biologic Therapies
10.1.3 On IBD in the Pakistani Context
10.1.4 On Any Preventative Measures that Can Be Taken
10.2 Professor John Hermon-Taylor, King's College London
10.2.1 The Significance of MAP in Crohn's
10.2.2 Rising Incidence of IBD
10.2.3 Defining IBD
10.2.4 Timeframe of MAP Vaccine
10.2.5 Antibiotic Activity of Other Crohn's Treatments
10.2.6 Alternative Treatments
10.2.7 Ethics of Crohn's Drug Development
10.2.8 The Impact of a Vaccine on the Market
10.2.9 On Claims that MAP is Not Implicated in CD
10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney
10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
10.3.2 IBD and HIV/AIDS
10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
10.3.4 Potential Cure?
10.3.5 Remicade and MAP10.3.6 Genotyping
10.3.7 Crohn's vs. Colitis
10.3.8 Future Therapies
10.3.9 The Potential and Future of Myoconda
11.1 IBD Market to Expand from 2013 to 2023
11.2 Aminosalicylates and Other Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatments
11.5 Future IBD Treatments: R&D Efforts Look Promising
11.6 The IBD Sector: Looking to the Future with Confidence
List of TablesTable 2.1 World Incidence Rates for IBD, 2013
Table 2.2 Geographical Variations in the Incidence of IBD, 2013
Table 3.1 Other Drug Types Used to Treat IBD, 2013
Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012
Table 4.2 Global IBD Drug Market Forecast ($m), 2012-2023
Table 4.3 Global IBD Drug Forecast by Drug Category ($m), 2012-2023
Table 4.4 Global IBD Drug Market Drivers and Restraints, 2012-2023
Table 4.5 Global Aminosalicylates Forecast ($m), 2012-2023
Table 4.6 Global Aminosalicylates Drivers and Restraints, 2012-2023
Table 4.7 Global Antibiotics Forecast ($m), 2012-2023
Table 4.8 Global Antibiotics Drivers and Restraints, 2012-2023
Table 4.9 Global Biologic Therapies Forecast ($m), 2012-2023
Table 4.10 Global Biologic Therapies Drivers and Restraints, 2012-2023
Table 4.11 Global Corticosteroid Forecast ($m), 2012-2023
Table 4.12 Global Corticosteroids Drivers and Restraints, 2012-2023
Table 4.13 Global Immunomodulators Forecast ($m), 2012-2023
Table 4.14 Global Immunomodulators Drivers and Restraints, 2012-2023
Table 5.1 Global IBD Drug Revenues by Geographical Segments ($m), 2012
Table 5.2 Global IBD Drug Market Forecasts by Country ($m), 2012-2023
Table 5.3 US IBD Drug Market Forecast ($m), 2012-2023
Table 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023
Table 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023
Table 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023
Table 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023
Table 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023
Table 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023
Table 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023
Table 6.1 Leading IBD Treatments by Revenue ($m), 2012
Table 6.2 Leading IBD Medicines: Revenue Forecasts ($m), 2012-2023
Table 6.3 World Humira Revenue Forecast ($m), 2012-2023
Table 6.4 Drivers and Restraints for Humira, 2012-2023
Table 6.5 World Remicade Revenue Forecast ($m), 2012-2023
Table 6.6 Drivers and Restraints for Remicade, 2012-2023
Table 6.7 World Asacol Revenue Forecast ($m), 2012-2023
Table 6.8 Drivers and Restraints for Asacol, 2012-2023
Table 6.9 World Pentasa Revenue Forecast ($m), 2012-2023
Table 6.10 Drivers and Restraints for Pentasa, 2012-2023
Table 6.11 World Lialda Revenue Forecast ($m), 2012-2023
Table 6.12 Drivers and Restraints for Lialda, 2012-2023
Table 6.13 World Tysabri Revenue Forecast ($m), 2012-2023
Table 6.14 Drivers and Restraints for Tysabri, 2012-2023
Table 6.15 World Xifaxan Revenue Forecast ($m), 2012-2023
Table 6.16 Drivers and Restraints for Xifaxan, 2012-2023
Table 6.17 World Cimzia Revenue Forecast ($m), 2012-2023
Table 6.18 Drivers and Restraints for Cimzia, 2012-2023
Table 6.19 World Entocort Revenue Forecast ($m), 2012-2023
Table 6.20 Drivers and Restraints for Entocort, 2012-2023
Table 6.21 World Neoral Revenue Forecast ($m), 2012-2023
Table 6.22 Drivers and Restraints for Neoral, 2012-2023
Table 6.23 World Medrol Revenue Forecast ($m), 2012-2023
Table 6.24 Drivers and Restraints for Medrol, 2012-2023
Table 6.25 World Canasa Revenue Forecast ($m), 2012-2023
Table 6.26 Drivers and Restraints for Canasa, 2012-2023
Table 6.27 World Apriso Revenue Forecast ($m), 2012-2023
Table 6.28 Drivers and Restraints for Apriso, 2012-2023
Table 6.29 World Azulfidine Revenue Forecast ($m), 2012-2023
Table 6.30 Drivers and Restraints for Azulfidine, 2012-2023
Table 7.1 Selected IL Inhibitors in Clinical Development, 2013
Table 7.2 Selected CAM Inhibitors in Clinical Development, 2013
Table 7.3 Selected TNF-Alfa Inhibitors in Clinical Development, 2013
Table 7.4 Selected Stem Cell Therapies in Clinical Development, 2013
Table 7.5 Selected Immunomodulators in Clinical Development, 2013
Table 7.6 Selected Chemokine Receptors in Clinical Development, 2013
Table 7.7 Selected Antioxidants and Barrier Function Therapies in Clinical Development, 2013
Table 8.1 SWOT Analysis of the World IBD Drug Market, 2012-2023
Table 8.2 STEP Analysis of the World IBD Drug Market, 2012-2023
Table 9.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2012
Table 9.2 AbbVie Revenues ($m) and Market Share (%), 2012
Table 9.3 Janssen Biotech Revenues ($m) and Market Share (%), 2012
Table 9.4 Warner Chilcott Revenues ($m) and Market Share (%), 2012
Table 9.5 Shire's Revenues ($m) and Market Share (%), 2012
Table 11.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Product Category, 2013, 2017, 2023
Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Geographical Regions, 2013, 2017, 2023
Table 11.3 Summary of IBD Market Drivers and Restraints, 2013-2023
List of FiguresFigure 3.1 Treatment Protocol for IBD, 2013
Figure 4.1 World IBD Drugs Market Shares by Product Type (%), 2012
Figure 4.2 Global IBD Drug Market Forecast ($m), 2012-2023
Figure 4.3 World IBD Drugs Market Shares by Product Type (%), 2023
Figure 4.4 Global Aminosalicylates Forecast ($m), 2012-2023
Figure 4.5 Global Antibiotics Forecast ($m), 2012-2023
Figure 4.6 Global Biologic Therapies Forecast ($m), 2012-2023
Figure 4.7 Global Corticosteroid Forecast ($m), 2012-2023
Figure 4.8 Global Immunomodulators Forecast ($m), 2012-2023
Figure 5.1 Global IBD Drug Market by Geographical Segments (%), 2012
Figure 5.2 Global IBD Drug Market by Geographical Segments (%), 2023
Figure 5.3 US IBD Drug Market Forecast ($m), 2012-2023
Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023
Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023
Figure 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023
Figure 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023
Figure 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023
Figure 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023
Figure 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023
Figure 6.1 World Humira Revenue Forecast ($m), 2012-2023
Figure 6.2 World Remicade Revenue Forecast ($m), 2012-2023
Figure 6.3 World Asacol Revenue Forecast ($m), 2012-2023
Figure 6.4 World Pentasa Revenue Forecast ($m), 2012-2023
Figure 6.5 World Lialda Revenue Forecast ($m), 2012-2023
Figure 6.6 World Tysabri Revenue Forecast ($m), 2012-2023
Figure 6.7 World Xifaxan Revenue Forecast ($m), 2012-2023
Figure 6.8 World Cimzia Revenue Forecast ($m), 2012-2023
Figure 6.9 World Entocort Revenue Forecast ($m), 2012-2023
Figure 6.10 World Neoral Revenue Forecast ($m), 2012-2023
Figure 6.11 World Medrol Revenue Forecast ($m), 2012-2023
Figure 6.12 World Canasa Revenue Forecast ($m), 2012-2023
Figure 6.13 World Apriso Revenue Forecast ($m), 2012-2023
Figure 6.14 World Azulfidine Revenue Forecast ($m), 2012-2023
Figure 9.1 Top 4 Companies for IBD Drugs: Market Shares (%), 2012
Aga Khan University Hospital
Cambridge Antibody Technology
Celgene Cellular Therapies
Centocor Ortho Biotech
Centre for Digestive Diseases, Sydney
Centres for Disease Control and Prevention
Crohn's and Colitis Foundation of America
Crohn's and Colitis Foundation of Canada
European Federation of Crohn's and Ulcerative Colitis Associations
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Johnson & Johnson
King's College London
Kyorin Pharmaceutical Co.
Merck & Co.
Otsuka Pharmaceutical Group
Probiotic Therapy Research Centre, Sydney, Australia
Procter & Gamble Pharmaceuticals
Shire Pharmaceuticals Group
Teva Pharmaceutical Industries
World Gastroenterology Organisation (WGO)
To order this report:Drug_and_Medication Industry: Inflammatory Bowel Diseases: World Drug Market 2013-2023
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
Aug. 4, 2015 06:45 PM EDT Reads: 231
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Aug. 4, 2015 06:45 PM EDT Reads: 215
SYS-CON Events announced today that the "Second Containers & Microservices Expo" will take place November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
Aug. 4, 2015 05:30 PM EDT
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
Aug. 4, 2015 05:00 PM EDT Reads: 107
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Aug. 4, 2015 03:00 PM EDT Reads: 573
Scrum Alliance has announced the release of its 2015 State of Scrum Report. Almost 5,000 individuals and companies worldwide participated in this year's survey. Most organizations in the market today are still leading and managing under an Industrial Age model. Not only is the speed of change growing exponentially, Agile and Scrum frameworks are showing companies how to draw on the full talents and capabilities of those doing the work in order to continue innovating for success.
Aug. 4, 2015 02:45 PM EDT
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Aug. 4, 2015 02:00 PM EDT Reads: 387
Between the compelling mockups and specs produced by your analysts and designers, and the resulting application built by your developers, there is a gulf where projects fail, costs spiral out of control, and applications fall short of requirements. In his session at @DevOpsSummit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, presented a new approach where business and development users collaborate – each using tools appropriate to their goals and expertise – to build mocku...
Aug. 4, 2015 01:30 PM EDT
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Aug. 4, 2015 01:00 PM EDT Reads: 292
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Aug. 4, 2015 12:00 PM EDT Reads: 113
Graylog, Inc., has added the capability to collect, centralize and analyze application container logs from within Docker. The Graylog logging driver for Docker addresses the challenges of extracting intelligence from within Docker containers, where most workloads are dynamic and log data is not persisted or stored. Using Graylog, DevOps and IT Ops teams can pinpoint the root cause of problems to deliver new applications faster and minimize downtime.
Aug. 4, 2015 11:45 AM EDT
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Aug. 4, 2015 11:30 AM EDT Reads: 115
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Aug. 4, 2015 09:30 AM EDT Reads: 112
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Aug. 4, 2015 08:45 AM EDT Reads: 261
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Aug. 4, 2015 07:00 AM EDT Reads: 226